文献速递传染病防控与疫情报告卫生政策与健康促进

曼氏血吸虫新疫苗单独或联合大规模给药的政策启示

Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration.
PubMed 文献 · Vaccine · 2020-05-14

本文用随机个体模型分析曼氏血吸虫候选疫苗单独或联合吡喹酮大规模给药(MDA)实现WHO控制目标的策略。结果显示低至中度传播下疫苗与MDA均可能在15年内达标且具成本效益;高传播下MDA单独无法达标,疫苗联合MDA可达成目标且具成本效益。

要点

  • 低至中度传播下,疫苗与MDA均可能在15年内实现WHO目标且具成本效益。
  • 高传播下MDA单独无法达标,疫苗联合MDA可实现两个目标。
  • 高传播下疫苗全程接种费用达7.60美元时仍具成本效益。

核心结论

  • 低至中度传播下疫苗与MDA均可能15年内达WHO目标且具成本效益。
  • 高传播下MDA单独无法达标,疫苗联合MDA可实现两个目标。
  • 疫苗公共卫生价值取决于保护持续时间、基线患病率和WHO目标。

研究设计与样本

  • 采用随机个体模型分析疫苗或联合MDA与单独MDA的策略比较。

主要发现

  • 低至中度传播下疫苗与MDA均可能在15年内达WHO目标且具成本效益。
  • 高传播下MDA单独无法达标,而疫苗联合MDA可实现两个目标。
  • 高传播下疫苗即使保护期短,全程接种费用达7.60美元时仍具成本效益。

关键数值与推荐

  • WHO设定了2020年和2025年两个控制目标:发病率控制和消除作为公共卫生问题(EPHP)。
  • 高传播下疫苗全程接种费用达7.60美元时仍具成本效益。

临床怎么用

  • 低至中度传播地区可考虑疫苗或MDA作为控制策略。
  • 高传播地区需疫苗联合MDA以实现WHO目标。
  • 疫苗决策需结合保护持续时间、基线患病率和目标综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schistosomiasis is one of the most important neglected tropical diseases (NTDs) affecting millions of people in 79 different countries. The World Health Organization (WHO) has specified two control goals to be achieved by 2020 and 2025 - morbidity control and elimination as a public health problem (EPHP). Mass drug administration (MDA) is the main method for schistosomiasis control but it has sometimes proved difficult to both secure adequate supplies of the most efficacious drug praziquantel to treat the millions infected either annually or biannually, and to achieve high treatment coverage in targeted communities in regions of endemic infection. The development of alternative control methods remains a priority. In this paper, using stochastic individual-based models, we analyze whether the addition of a novel vaccine alone or in combination with drug treatment, is a more effective control strategy, in terms of achieving the WHO goals, as well as the time and costs to achieve these goals when compared to MDA alone. The key objective of our analyses is to help facilitate decision making for moving a promising candidate vaccine through the phase I, II and III trials in humans to a final product for use in resource poor settings. We find that in low to moderate transmission settings, both vaccination and MDA are highly likely to achieve the WHO goals within 15 years and are likely to be cost-effective. In high transmission settings, MDA alone is unable to achieve the goals, whereas vaccination is able to achieve both goals in combination with MDA. In these settings Vaccination is cost-effective, even for short duration vaccines, so long as vaccination costs up to US$7.60 per full course of vaccination. The public health value of the vaccine depends on the duration of vaccine protection, the baseline prevalence prior to vaccination and the WHO goal.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kura K, Collyer BS, Toor J, et al. Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration. Vaccine. 2020. PMID: 32418795. doi:10.1016/j.vaccine.2020.04.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。